Rogers (ROG) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Rogers Corporation Reports Results for the 2016 Third Quarter
November 2, 2016 4:23 PM EDTNet sales of $165.3 million, up 3.1% Gross margin of 37.5%, up 30 basis points Net income of $16.1 million, up 28.1% Adjusted EBITDA of $34.1 million, 20.6% of net sales
ROGERS, Conn.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) today announced financial results for the 2016 third... More
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
November 2, 2016 1:00 AM EDT15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra data from GiACTA - the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy in more than 50 years New data from two studies investigating cardiovascular outcomes for people with rheumatoid arthritis (RA) treated with Actemra
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),... More



